ADPT · Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp Is A Company Advancing The Field Of Immune-Driven Medicine By Harnessing The Inherent Biology Of The Adaptive Immune System To Transform The Diagnosis And Treatment Of Disease. Its Clinical Diagnostic Product, Clonoseq, Is A Test Authorized By The Fda For The Detection And Monitoring Of Minimal Residual Disease (Mrd) In Patients With Multiple Myeloma (Mm), B Cell Acute Lymphoblastic Leukemia (All) And Chronic Lymphocytic Leukemia (Cll) And Is Also Available As A Clia-Validated Laboratory Developed Test (Ldt) For Patients With Other Lymphoid Cancers. The Company Has Two Operating Segments: Minimal Residual Disease And Immune Medicine. The Company Generates The Majority Of Its Revenue From The Minimal Residual Disease Segment.